MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate

MYC通过重编程神经内分泌命运驱动小细胞肺癌亚型的时间演变

阅读:4
作者:Abbie S Ireland ,Alexi M Micinski ,David W Kastner ,Bingqian Guo ,Sarah J Wait ,Kyle B Spainhower ,Christopher C Conley ,Opal S Chen ,Matthew R Guthrie ,Danny Soltero ,Yi Qiao ,Xiaomeng Huang ,Szabolcs Tarapcsák ,Siddhartha Devarakonda ,Milind D Chalishazar ,Jason Gertz ,Justin C Moser ,Gabor Marth ,Sonam Puri ,Benjamin L Witt ,Benjamin T Spike ,Trudy G Oliver

Abstract

Small cell lung cancer (SCLC) is a neuroendocrine tumor treated clinically as a single disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based on expression of ASCL1, NEUROD1, POU2F3, or YAP1. Here, we use mouse and human models with a time-series single-cell transcriptome analysis to reveal that MYC drives dynamic evolution of SCLC subtypes. In neuroendocrine cells, MYC activates Notch to dedifferentiate tumor cells, promoting a temporal shift in SCLC from ASCL1+ to NEUROD1+ to YAP1+ states. MYC alternatively promotes POU2F3+ tumors from a distinct cell type. Human SCLC exhibits intratumoral subtype heterogeneity, suggesting that this dynamic evolution occurs in patient tumors. These findings suggest that genetics, cell of origin, and tumor cell plasticity determine SCLC subtype.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。